2019
Report from the European Society of Thoracic Surgeons prospective thymic database 2017: a powerful resource for a collaborative global effort to manage thymic tumours
Ruffini E, Guerrera F, Brunelli A, Passani S, Pellicano D, Thomas P, Van Raemdonck D, Rocco G, Venuta F, Weder W, Detterbeck F, Falcoz PE. Report from the European Society of Thoracic Surgeons prospective thymic database 2017: a powerful resource for a collaborative global effort to manage thymic tumours. European Journal Of Cardio-Thoracic Surgery 2019, 55: 601-609. PMID: 30649256, DOI: 10.1093/ejcts/ezy448.Peer-Reviewed Original ResearchConceptsNeuroendocrine thymic tumoursThymic tumorsAdjuvant treatmentThymic carcinomaStage IStage IIIB tumorsEuropean SocietyStage IV tumorsOverall recurrence rateInvasive surgical approachNew International AssociationCollaborative global effortIIIB tumorsProspective databaseStage IIIAMetastasis classificationRecurrence rateGroup tumorsRare tumorSurgical approachRetrospective databaseInvasive techniquesStage IIIPatientsTumors
2013
Treatment of Stage III Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, Diekemper R, Detterbeck FC, Arenberg DA. Treatment of Stage III Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST Journal 2013, 143: e314s-e340s. PMID: 23649445, DOI: 10.1378/chest.12-2360.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerLung cancerDefinitive chemoradiationNeoadjuvant therapyStage IIIARandomized trialsPractice guidelinesAmerican CollegeChest Physicians Evidence-Based Clinical Practice GuidelinesEvidence-based clinical practice guidelinesNon-small cell lung cancer diagnosisLow perioperative mortality ratePlatinum-based adjuvant chemotherapyStage IIIA lung cancerStage III lung cancerCell lung cancer diagnosisIIIA lung cancerMicroscopic nodal metastasesProphylactic cranial radiationChest Physicians guidelinesPerioperative mortality rateCell lung cancerClinical practice guidelinesStrength of recommendationsLung cancer diagnosis
2004
Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non–Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial
Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman JG. Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non–Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial. Journal Of Clinical Oncology 2004, 22: 4341-4350. PMID: 15514375, DOI: 10.1200/jco.2004.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveCamptothecinCarboplatinCarcinoma, Non-Small-Cell LungCombined Modality TherapyFemaleHumansIrinotecanLung NeoplasmsMaleMiddle AgedNeoplasm StagingPaclitaxelRadiotherapy, ConformalRemission InductionSurvival AnalysisTreatment OutcomeConceptsStage III NSCLC patientsCell lung cancerClinical target volumeConcurrent chemotherapyConformal radiation therapyNSCLC patientsPerformance statusLung cancerRadiation therapyDose-escalation phase I trialTarget volumeConventional radiotherapy dosesUnresectable stage IIIAGood performance statusLocal control rateMaximum-tolerated doseDose-limiting toxicityPhase I trialMedian survival timeOverall response rateInitial clinical target volumeInduction chemotherapyFatal hemoptysisLate toxicityStage IIIA